Related references
Note: Only part of the references are listed.Type 1 Diabetes Treatment Beyond Insulin
Lindsay B. Harrison et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2016)
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes
Jeffrey L. Probstfield et al.
DIABETES CARE (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
Caroline Bonner et al.
NATURE MEDICINE (2015)
Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
Robert R. Henry et al.
DIABETES CARE (2015)
Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?
David Z. I. Cherney et al.
CANADIAN JOURNAL OF DIABETES (2014)
Once-Weekly Exenatide as Adjunct Treatment of Type 1 Diabetes Mellitus in Patients Receiving Continuous Subcutaneous Insulin Infusion Therapy
Andrea N. Traina et al.
CANADIAN JOURNAL OF DIABETES (2014)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
David Z. I. Cherney et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges
Tara Ghazi et al.
DIABETES CARE (2014)
Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
Gayatri Sarkar et al.
DIABETES CARE (2014)
Sodium- Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open- Label Proof- ofConcept Trial
Bruce A. Perkins et al.
DIABETES CARE (2014)
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
Elizabeth M. Lamos et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport
M. A. Abdul-Ghani et al.
JOURNAL OF INTERNAL MEDICINE (2014)
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial
Kurt J. Griffin et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
The Emerging Global Epidemic of Type 1 Diabetes
Jaakko Tuomilehto
CURRENT DIABETES REPORTS (2013)
Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study
D. Pitocco et al.
DIABETES OBESITY & METABOLISM (2013)
Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study
K. V. S. Hari Kumar et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2013)
LIRAGLUTIDE AS ADDITIONAL TREATMENT TO INSULIN IN OBESE PATIENTS WITH TYPE 1 DIABETES MELLITUS
Nitesh D. Kuhadiya et al.
ENDOCRINE PRACTICE (2013)
A review of the efficacy and safety of oral antidiabetic drugs
Stephanie Aleskow Stein et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Metformin for the Treatment of Hyperandrogenism in Adolescents with Type 1 Diabetes Mellitus
Ethel Codner et al.
HORMONE RESEARCH IN PAEDIATRICS (2013)
Effect of Pioglitazone on the Course of New-Onset Type 1 Diabetes Mellitus
Kimberly Sue Tafuri et al.
JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY (2013)
Experiences of using blood glucose targets when following an intensive insulin regimen: a qualitative longitudinal investigation involving patients with Type 1 diabetes
D. Rankin et al.
DIABETIC MEDICINE (2012)
Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function
Urd Kielgast et al.
DIABETES CARE (2011)
Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial
S. K. Garg et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial
S. L. Ellis et al.
DIABETIC MEDICINE (2011)
Liraglutide as additional treatment for type 1 diabetes
Ajay Varanasi et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes
Vandana S. Raman et al.
DIABETES CARE (2010)
The use of metformin in type 1 diabetes: a systematic review of efficacy
S. Vella et al.
DIABETOLOGIA (2010)
Effect of Glucagon-Like Peptide-1 on α- and β-Cell Function in C-Peptide-Negative Type 1 Diabetic Patients
Urd Kielgast et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients
Sayaka Kubo et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 Diabetes
Kristina I. Rother et al.
DIABETES CARE (2009)
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes
S. S. Lund et al.
DIABETES OBESITY & METABOLISM (2009)
Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study
Zhifang Yang et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Combination Therapy With Glucagon-Like Peptide-1 and Gastrin Restores Normoglycemia in Diabetic NOD Mice
Wilma L. Suarez-Pinzon et al.
DIABETES (2008)
Beta cell mass in diabetes: a realistic therapeutic target?
J. J. Meier
DIABETOLOGIA (2008)
Effect of Vildagliptin on Glucagon Concentration During Meals in Patients with Type 1 Diabetes
J. E. Foley et al.
HORMONE AND METABOLIC RESEARCH (2008)
Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study
Soren Sogaard Lund et al.
PLOS ONE (2008)
The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial
Monique L. Stone et al.
PEDIATRIC DIABETES (2008)
Effect of pioglitazone therapy in lean type1 diabetes mellitus
R. Bhat et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes
Vera Zdravkovic et al.
JOURNAL OF PEDIATRICS (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
The effect of rosiglitazone on overweight subjects with type 1 diabetes
SM Strowig et al.
DIABETES CARE (2005)
Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus
D Neuser et al.
CLINICAL DRUG INVESTIGATION (2005)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes
J Dupré et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes:: randomised placebo-controlled trial with aspects on insulin sensitivity
S Särnblad et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003)
Metformin as an adjunct theraphy in adolescents with type 1 diabetes and insulin resistance
J Hamilton et al.
DIABETES CARE (2003)
Insulin resistance in type 1 diabetes
CJ Greenbaum
DIABETES-METABOLISM RESEARCH AND REVIEWS (2002)
Voglibose administration before the evening meal improves nocturnal hypoglycemia in insulin-dependent diabetic patients with intensive insulin therapy
M Taira et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2000)
Share Paper
